Journal article · 2020 · Open access
Alzheimer's disease drug development pipeline: 2020
Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050 · Published 1 January 2020 · DOI 10.1002/trc2.12050
In brief
“Alzheimer's disease drug development pipeline: 2020” is a 2020 journal article by Jeffrey L. Cummings and 4 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 597 citations as of 15 November 2026, which puts it in the top 1% of works published in 2020 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 597
- Most cited in
- 2021 (192)
- Field-weighted impact
- 41.96
- References
- 49
- Authors
- 5
Abstract
INTRODUCTION: Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related Dementias Research Ontology (CADRO) to classify treatment targets and mechanisms of action. We review our annual pipeline reports for the past 5 years to provide longitudinal insight into clinical trials and drug development for AD. METHODS: We reviewed ClinicalTrials.gov as of February 27, 2020, and identified all trials of pharmacologic agents currently being developed for treatment of AD as represented on this widely used U.S. Food and Drug Administration registry. RESULTS: There are 121 agents in clinical trials for the treatment of AD. Twenty-nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement and 12 are intended to treat neuropsychiatric and behavioral symptoms. There are 97 agents in disease modification trials. Compared to the 2019 pipeline, there is an increase in the number of disease-modifying agents targeting pathways other than amyloid or tau. DISCUSSION: The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. Review of clinical trials over the past 5 years show that there is progressive emphasis on non-amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. There has been a marked growth in repurposed agents in the pipeline.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050. https://doi.org/10.1002/trc2.12050
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2020.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 6, no. 1, 2020, p. e12050. https://doi.org/10.1002/trc2.12050.
Chicago
Cummings, Jeffrey L., Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, and Kate Zhong. 2020. “Alzheimer's disease drug development pipeline: 2020.” Alzheimer s & Dementia Translational Research & Clinical Interventions 6 (1): e12050. https://doi.org/10.1002/trc2.12050.
Harvard
Cummings, J. L. et al. (2020) ‘Alzheimer's disease drug development pipeline: 2020’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), p. e12050. doi:10.1002/trc2.12050.
IEEE
J. L. Cummings, G. Lee, A. R. Ritter, M. N. Sabbagh, and K. Zhong, “Alzheimer's disease drug development pipeline: 2020,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 6, no. 1, p. e12050, 2020, doi: 10.1002/trc2.12050.
BibTeX
@article{cummings2020alzheimer,
title = {{Alzheimer's disease drug development pipeline: 2020}},
author = {Cummings, Jeffrey L. and Lee, Garam and Ritter, Aaron R. and Sabbagh, Marwan Noel and Zhong, Kate},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2020},
volume = {6},
number = {1},
pages = {e12050},
doi = {10.1002/trc2.12050},
url = {https://doi.org/10.1002/trc2.12050}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 32 | |
| 2021 | 192 | |
| 2022 | 162 | |
| 2023 | 56 | |
| 2024 | 60 | |
| 2025 | 52 | |
| 2026 | 43 |
Its field-weighted citation impact is 41.96: it has been cited 41.96 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- disease-modifying therapy
- amyloid
- tau protein
- cognitive enhancement
- neuropsychiatric symptoms
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050. https://doi.org/10.1002/trc2.12050
How many times has this paper been cited?
597 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, Kate Zhong.
What is the DOI of this paper?
10.1002/trc2.12050. The permanent link is https://doi.org/10.1002/trc2.12050.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.